MBX Biosciences Inc
MBX Biosciences Inc (MBX) Wheel Strategy
MBX wheel strategy scan found 23 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 86.9%.
Read more
Running a MBX wheel strategy lets you generate consistent premium income on MBX Biosciences Inc while setting your own entry and exit prices on the underlying. MBX Biosciences Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own MBX, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best MBX wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on MBX, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable MBX wheel from a losing one.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the MBX wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your MBX wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Oct 16, 2026 | 60.00 | $2.00 | $4.00 | -0.37 | 28 | 6% | 55.7% | 86.9% | 12 |
| Nov 20, 2026 | 60.00 | $5.00 | $6.75 | -0.37 | 63 | 6% | 50.8% | 65.2% | 4 |
| Oct 16, 2026 | 55.00 | $0.10 | $2.50 | -0.25 | 28 | 6% | 71.4% | 59.3% | 3 |
| Dec 18, 2026 | 55.00 | $6.00 | $7.85 | -0.30 | 91 | 6% | 57.9% | 57.2% | 1 |
| Jan 15, 2027 | 55.00 | $7.50 | $9.65 | -0.29 | 119 | 6% | 55.2% | 53.8% | 4 |
| Dec 18, 2026 | 50.00 | $5.30 | $6.45 | -0.24 | 91 | 6% | 67.5% | 51.7% | 5 |
| Jan 15, 2027 | 50.00 | $6.00 | $7.65 | -0.24 | 119 | 6% | 63.8% | 46.9% | 2 |
| Nov 20, 2026 | 55.00 | $2.50 | $4.35 | -0.28 | 63 | 6% | 61.8% | 45.8% | 1 |
| Jan 15, 2027 | 45.00 | $3.10 | $5.30 | -0.19 | 119 | 6% | 72.5% | 36.1% | 5 |
| Nov 20, 2026 | 50.00 | $0.85 | $2.88 | -0.20 | 63 | 6% | 72.8% | 33.3% | 1 |
As of September 18, 2026
Run the Wheel on MBX With Confidence
Find the best MBX wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.
Start your 14-day free trial→